Evidence map›Paper›PMID 39514167›Full record

ReviewMolecular diagnosis & therapy2025

Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [

Priscilla Guglielmo, Cinzia Crivellaro, Angelo Castello, Carminia Maria Della Corte, Maria Pagano, Silvia Marchesi, Mario Occhipinti, Paolo Andrea Zucali, Laura Evangelista

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06790082 (FAPI PET in Pleural Mesothelioma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06790082 phase2recruitingnot on this map

FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation

TypeinterventionalSponsorAalborg University HospitalRan2025 to 2037Enrolled70ConditionsPleural Mesothelioma, Pleural Diseases, Cancer, FAPIArms[68Ga]Ga-FAPI-46 PET/CT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Priscilla GuglielmoNuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy.ORCID 0000-0001-9150-4367
Cinzia CrivellaroNuclear Medicine, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.ORCID 0000-0002-2645-5236
Angelo CastelloNuclear Medicine Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0002-5868-3372
Carminia Maria Della CorteDipartimento di Medicina di Precisione, Università della Campania "Luigi Vanvitelli," Napoli, Naples, Italy.ORCID 0000-0002-3396-8099
Maria PaganoMedical Oncology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.ORCID 0000-0001-5418-5168
Silvia MarchesiMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.ORCID 0009-0006-5781-7726
Mario OcchipintiMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.ORCID 0000-0002-7169-5343
Paolo Andrea ZucaliDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.ORCID 0000-0002-2274-1702
Laura EvangelistaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. laura.evangelista@hunimed.eu.ORCID 0000-0002-5955-9488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesothelioma is a malignant tumor associated primarily with asbestos exposure, characterized by an aggressive nature and poor prognosis. Accurate diagnosis, staging, and monitoring of therapeutic response are crucial for effective patient management. Along with a computed tomography (CT) scan, fluorodeoxyglucose labeled with fluorine-18 ([

Indexed as

Fluorodeoxyglucose F18MesotheliomaPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsHumansMesothelioma, MalignantFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.